Research Reports

Key takeaways

Bridget Ross notified the Board on April 8, 2026 of her intent not to stand for re-election as a Class II director at the June 2, 2026 Annual Meeting.

Ms. Ross's departure is not due to any disagreement with the Company regarding operations, policies, or practices.

David B. Roberts was nominated for election as a Class II director; he will resign as a Class I director contingent upon his election.

The Board reduced its size from eight to seven members, effective immediately upon Ms. Ross's departure at the conclusion of the Annual Meeting.

Following the Annual Meeting, the Board will consist of two Class I, two Class II, and three Class III directors.

Full analysis

Bridget Ross, a Class II director, informed the Board on April 8, 2026, that she will not seek re-election at the upcoming Annual Meeting scheduled for June 2, 2026. She will continue to serve until her term expires. The filing explicitly states her departure is unrelated to any disagreement with the Company. To rebalance the board classes, David B. Roberts, currently a Class I director, was nominated for the Class II seat. Consequently, the Board took action to reduce its size from eight to seven members, effective upon Ms. Ross's departure. This reduction eliminates the vacant Class I directorship resulting from Mr. Roberts's conditional resignation.

LMAT · LeMaitre Vascular, Inc.

Summary

Key takeaways

Full analysis